Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Core Viewpoint - The U.S. FDA has lifted the clinical hold on Intellia Therapeutics' Investigational New Drug application for the MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z) for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM) [1][2] Group 1: Clinical Trials - The MAGNITUDE trial is a randomized, double-blind, placebo-controlled study involving approximately 1,200 patients with ATTR-CM, focusing on cardiovascular-related events as the primary endpoint [3] - The MAGNITUDE-2 trial is also a randomized, double-blind, placebo-controlled study, but it targets around 60 patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN), with primary endpoints including changes in neuropathy impairment scores and serum TTR levels [4] Group 2: Safety Measures and FDA Collaboration - The FDA had previously imposed clinical holds on both MAGNITUDE and MAGNITUDE-2 trials due to safety concerns, specifically elevated liver transaminases and bilirubin levels in a patient [2] - Intellia has collaborated with the FDA to implement enhanced safety measures, including increased monitoring of liver tests and exclusion criteria for patients with certain liver abnormalities and cardiovascular instability [2] Group 3: Product Information - Nex-z is based on CRISPR/Cas9 gene editing technology and aims to be the first one-time treatment for ATTR-CM and hereditary ATTR with polyneuropathy [5] - Interim Phase 1 clinical data indicated that nex-z led to significant and lasting reductions in TTR levels, and it has received Orphan Drug and RMAT Designations from the FDA [5] Group 4: Company Overview - Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on leveraging CRISPR gene editing to develop potentially curative treatments for severe diseases [6]